Press Releases

Jupiter, Fla., March 11, 2014 – Dyadic International, Inc. (“Dyadic”) (OTCQX: DYAI), a global biotechnology company, today announced that it has been approved for trading on OTCQX, the best marketplace for qualified companies.

Shares of Dyadic begin trading today on OTCQX U.S. Premier, a segment of the OTCQX marketplace reserved for world-leading U.S. companies that meet financial standards and provide timely news and disclosures to investors. Investors can find current financial disclosure and Real-Time Level 2 quotes for Dyadic

Dyadic’s Chief Financial Officer, Michael Faby stated, “Joining OTCQX clearly demonstrates our commitment to providing our shareholders access to a trading platform that we think will attract larger institutional investors and generate greater market interest in Dyadic.”

Dyadic’s Chief Executive Officer, Mark Emalfarb added, “Our admission to OTCQX is just the next step to Dyadic once again becoming an SEC reporting company traded on a registered national exchange. While we continue to evaluate our uplisting opportunities, we believe this step shows our commitment to full transparency, to providing our shareholders greater liquidity, and access to one of the most trusted and reliable trading platforms available today.”

Dyadic has retained B. Riley & Co., LLC to serve as its Investment Banking Designated Advisor for Disclosure (“DAD”).

Dyadic will continue to trade under the symbol “DYAI.”


Dyadic International, Inc. is a global biotechnology company that uses its patented and proprietary technologies to conduct research, development and commercial activities for the discovery, development, manufacture and sale of enzymes and other proteins for the bioenergy, bio-based chemical, biopharmaceutical and industrial enzyme industries. Dyadic utilizes an integrated technology platform based on its patented and proprietary C1 microorganism, which enables the development and large scale manufacture of low cost enzymes and other proteins for diverse market opportunities. The C1 platform technology can also be used to screen for the discovery of novel genes. In addition to the sale of proprietary enzyme products, Dyadic actively pursues licensing arrangements and other commercial opportunities to leverage the value of these technologies by providing its partners and collaborators with the benefits of manufacturing and/or utilizing the enzymes and other proteins which these technologies help produce. Please visit Dyadic’s website at


Certain statements contained in this press release are “forward-looking statements” within the meaning of the federal securities laws. Statements about our beliefs and expectations regarding our technology platform, our licensing strategy and becoming an SEC reporting company may constitute forward-looking statements. These forward-looking statements involve risks, uncertainties and other factors that could cause Dyadic’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements in this press release. Investors are urged to consider these factors carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such forward-looking statements. Any forward-looking statements speak only as of the date of this press release and, except as required by law, Dyadic expressly disclaims any intent or obligation to update or revise any forward-looking statements to reflect actual results, any changes in expectations or any change in events. If Dyadic does update one or more forward-looking statements, no inference should be drawn that it will make additional updates with respect to those or other forward-looking statements. Factors that could cause results to differ materially include, but are not limited to: (1) general economic conditions, including the recent conditions in the global markets; (2) Dyadic’s ability to retain and attract employees; (3) competitive pressures and reliance on key customers and collaborators; and (4) other factors discussed in Dyadic’s publicly available filings, including the risk factors included in Dyadic’s Initial Information and Disclosure Statement to be filed with the OTC Markets Group.


Dyadic International, Inc.

Attention: Michael J. Faby

Vice President and Chief Financial Officer

Phone: 561-743-8333